T2DM (Type 2 Diabetes Mellitus)
Conditions
Keywords
T2DM, genetic polymorphism, diabetic nephropathy
Brief summary
Metformin is a classical oral antidiabetic drug, often recommended to be the first-choice treatment of type 2 diabetes mellitus (T2DM). Based on the previous research on PRKAA2, STK11 and diabetes, this study aimed to investigate the distributive characteristic of PRKAA2 and STK11 polymorphisms and the potential influence of STK11polymorphisms on metformin efficacy among Chinese T2DM patients, discuss the association of PRKAA2 polymorphisms between T2DM patients and healthy subjects.
Interventions
DRUGMetformin
Sponsors
People's Hospital of Zhengzhou University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* diagnosed with T2DM in keeping with the WHO criteria in 1999 \[14\], with fasting blood glucose (FBG) ≥ 7.0mmol ⁄ L and ⁄ or postprandial blood glucose (PBG) ≥ 11.1mmol ⁄ L; not using other antidiabetic drugs within the experimental period.
Exclusion criteria
* other significant illness such as cancer, myocardial infarction, stroke, severe liver, and kidney disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the incidence of T2DM | Jan 2014-Dec 2015 | people whose fasting plasma glucose ≥7.0 mmol/L and/or postprandial plasma glucose ≥11.1 mmol/L is diagnosed with T2DM. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| metformin efficacy----the decrease level of HbA1c | Jan 2014-Dec 2015 | patients whose HbA1c levels is decreased by more than 0.5 % from the baseline is deemed as the response group, while the decrease in HbA1c levels less than 0.5 % from the baseline is deemed as the non-response group. |
Outcome results
None listed